What it is
BAM15 is a small-molecule mitochondrial protonophore uncoupler (C₁₆H₁₀F₂N₆O, MW 340.29 g/mol, CAS 210302-17-3, PubChem CID 565708) built around a fused [1,2,5]oxadiazolo[3,4-b]pyrazine heterocycle with two 2-fluorophenyl anilines at the N5 and N6 positions. Unlike peptide entries in this database, BAM15 is a synthetic small molecule, not a protein or peptide. It was first described by Kenwood and Hoehn in Molecular Metabolism (2014) in the Santos lab at Virginia Tech. The aniline N-H is the ionizable group responsible for protonophoric activity; the extended π-system delocalizes the anion after deprotonation and allows the molecule to shuttle protons across the inner mitochondrial membrane in both protonated and deprotonated forms. Selectivity for mitochondrial inner membrane over plasma membrane is driven by the difference in membrane dipole potential between the two membranes (Tomar 2021). The compound is a solid off-white to pale-yellow powder handled from DMSO stock for in-vitro work and dosed orally (10–50 mg/kg in mice) in preclinical in-vivo studies. It is not a peptide, not a metabolite, and not a natural product.
In plain English
BAM15 is a lab-made small molecule. It is not a peptide, not a protein, not something your body makes. Scientists at Virginia Tech first described it in 2014. Its shape lets it slip back and forth across the inner wall of mitochondria (your cells' power plants), carrying a proton with it. That short-circuits the normal energy-storing step. Cells end up burning more fuel without making as much ATP (the body's energy currency). The key design feature: BAM15 targets the inner wall of the mitochondrion. It leaves the outer wall of the cell alone. That is supposed to make it safer than older drugs in the same family (like 2,4-DNP), which hit both. In the lab, it looks like an off-white powder. In mouse studies, it was given by mouth at 10–50 mg per kg of body weight.
How it works
- 01
Mitochondrial protonophore (inner-membrane selective)
BAM15 acts as a classical weak-acid protonophore: it picks up a proton in the acidic intermembrane space, diffuses across the inner mitochondrial membrane as the neutral species, releases the proton in the alkaline matrix, and returns as the membrane-permeable anion — short-circuiting the proton-motive force without engaging ATP synthase (Kenwood 2014, Mol Metab; Tomar 2021, BBA Biomembranes). The distinguishing feature versus FCCP is that BAM15's protonophoric activity is strongly modulated by membrane dipole potential, which is high in the mitochondrial inner membrane and lower in the plasma membrane. Phloretin (a dipole-potential reducer) suppresses BAM15's activity on planar bilayers, confirming the dipole-dependent mechanism. At 270 nM EC₅₀ for uncoupling in L6 myoblast mitochondria, BAM15 does not depolarize the plasma membrane — the safety property that separates it from both FCCP and 2,4-DNP.
In plain English
It makes mitochondria burn fuel without storing as much energy
Mitochondria normally build up a charge difference across their inner wall and use it to make ATP (the body's main energy currency). BAM15 punches a leak in that wall — it carries protons across and lets the charge bleed off. The cell has to burn more fuel to make up for the lost energy, so it uses up more fat and glucose. Unlike older drugs in the same family, BAM15 only leaks the inner mitochondrial wall, not the outer wall of the cell itself. That selectivity is the main thing that is supposed to make it safer than 2,4-DNP.
- 02
Increased substrate oxidation and energy expenditure
By dissipating the proton gradient, BAM15 drives electron-transport-chain turnover to maintain proton pumping, raising oxygen consumption without proportional ATP synthesis. In HFD-fed C57BL/6J mice at 10–50 mg/kg PO daily (Alexopoulos 2020, Nat Commun), this produced normalization of body weight without a change in food intake and without a change in body temperature. Substrate utilization shifted toward increased β-oxidation and glucose oxidation, and hepatic triglyceride content dropped. Kirkland 2020 (EMBO Mol Med) independently reproduced the effect in both prevention and treatment paradigms without tachyphylaxis over multi-week dosing.
In plain English
The body burns more fat and glucose without the mouse eating less
Because BAM15 makes mitochondria burn fuel less efficiently, the mouse has to oxidize more fat and sugar to keep up. In the 2020 studies, mice on a fattening diet returned to normal weight — without eating less and without running fevers. Their liver fat dropped too. Two independent labs saw the same thing, and the effect did not fade over weeks of dosing.
- 03
AMPK activation and metabolic reprogramming
Lowered cellular ATP/AMP ratio activates AMP-activated protein kinase. Kirkland 2020 showed AMPK-dependent enhancement of skeletal-muscle glucose uptake, ACC phosphorylation (suppressing lipogenesis), and activation of fatty-acid oxidation. Chronic AMPK signaling is the proposed route for PGC-1α upregulation and mitochondrial biogenesis reported in follow-on work. This mechanism overlaps with metformin's downstream signature but is driven by a fundamentally different proximal trigger (membrane-potential dissipation vs Complex I partial inhibition).
In plain English
It flips the cell's "low energy" switch, which turns on fat burning
When cells run low on energy (ATP), they turn on a master switch called AMPK. AMPK tells muscles to pull sugar out of the blood, tells the liver to stop making new fat, and tells cells to burn fat faster. BAM15 flips that switch by making cells feel low on energy. Metformin (a common diabetes drug) turns on the same switch, just through a different trigger.
- 04
Preserved lean mass — the feature that distinguishes BAM15 from calorie restriction
In the Ma 2024 head-to-head in female db/db mice (Mol Metab), BAM15 retained the largest percentage of lean mass among all weight-reducing arms, including semaglutide, rosiglitazone, and calorie restriction. The mechanistic reading is that increased mitochondrial turnover of fatty acids and glucose does not trigger the muscle-catabolic adaptive response that restricted intake or GLP-1-mediated anorexia produce. This is the reason BAM15 is interesting at all in a market where GLP-1 agonists already deliver large weight-loss effects.
In plain English
Mice lost fat but kept their muscle — unlike with dieting or semaglutide
When mice lose weight by eating less, or by taking semaglutide, they lose muscle too. In the 2024 head-to-head mouse study, BAM15 kept more muscle than any other weight-loss approach — semaglutide, an older diabetes drug, or just cutting calories. This is the main reason anyone cares about BAM15 in a world where GLP-1 drugs already exist: if the same muscle-sparing effect shows up in humans, it would be a real advantage. That "if" is still unproven.
- 05
Anti-inflammatory signal via immunometabolic reprogramming
Cheng 2021 (Int J Mol Sci) showed that BAM15 pretreatment reduced IL-6, TNF-α, and IL-10 in LPS-challenged mice and downregulated M1-macrophage polarization genes. Interpretation: reduced cellular ATP availability limits the energy-intensive M1 inflammatory program, mimicking the anti-inflammatory effect of caloric restriction without actual food restriction. This is a single-lab signal in an acute model; chronic inflammatory-disease models for BAM15 have not been published.
In plain English
A hint that it may calm inflammation — shown in one study in mice
Inflammatory immune cells need lots of energy to mount an attack. Because BAM15 makes energy harder to come by, one 2021 mouse study suggested it quieted down the pro-inflammatory response after a bacterial-toxin challenge. Just one lab, just one kind of challenge, and the mice had to be dosed before the challenge started. No studies of long-running inflammatory disease have been done.
- 06
What is NOT known about the mechanism in humans
Every mechanistic statement above comes from rodent, cell-culture, or planar-bilayer work. No human PK has been published. The reported ~1.7 h half-life and high lipophilicity are rodent / in-silico values — they have not been validated in human subjects. The concentration range that uncouples mouse mitochondria in vivo has not been mapped to a human plasma exposure. Whether BAM15 produces the same lean-mass-preserving, temperature-neutral profile in humans at therapeutically uncoupling exposures is the central open question, and it is exactly what a well-designed Phase 1 MAD would answer.
In plain English
What we still don't know
Every statement above comes from mice, cells in dishes, or computer modeling. No study has measured what BAM15 does in a human body. The 1.7-hour half-life is a number from animals and simulations — it has not been confirmed in people. We also don't know the human dose range: how much it would take to make a human burn more fat without burning them out. Whether the muscle-sparing, no-fever profile from mice will carry over to humans is the big open question. A proper Phase 1 human trial is exactly what would answer it.